Affiliation:
1. Antibiotic Discovery and Development, Merck Research Laboratories, Rahway, New Jersey 07065
Abstract
ABSTRACT
MK-826 (formerly L-749,345), is a potent 1-β-methyl carbapenem with a long half-life and broad spectrum of activity. This compound is presently in phase-II clinical trials. Its activity against a number of gram-positive and gram-negative organisms was compared to those of imipenem (IPM) and eight other β-lactam agents in two in vivo murine infection models. The distribution in tissue and pharmacokinetic properties of MK-826 and ceftriaxone (CTRX) were also evaluated in CD-1 mice following a single intraperitoneal dose (10 mg/kg of body weight). In addition, concentrations in plasma as well as biliary and urinary recovery of MK-826 were compared to that of CTRX in a cannulated rat model. In a localized murine thigh infection model, MK-826 and IPM were superior to a variety of β-lactam antibiotics in reduction of
Staphylococcus aureus
CFU compared with results from nontreated controls (eliminating ≥4 log
10
CFU). Similar activities of IPM and MK-826 were observed in a gram-positive bacterial murine systemic infection model. While IPM demonstrated greater efficacy than MK-826 against
Enterobacter cloacae
(50% effective doses [ED
50
s] of 0.062 and 0.227 mg/kg, respectively) and
Pseudomonas aeruginosa
(ED
50
s of 0.142 and 3.0 mg/kg, respectively) systemic infections, MK-826 was 8- to 350-fold more efficacious than IPM against all other gram-negative organisms in this infection model. In mice, MK-826 demonstrated a higher peak concentration in serum (62.8 versus 42.6 μg/ml) and a larger area under the curve (AUC) (150.8 versus 90.0 μg · hr/ml) than CTRX. The concentrations of MK-826 and CTRX in serum declined slowly, with levels of 3.6 and 2.0 μg/ml remaining, respectively, at 6 h posttreatment. The rat pharmacokinetic model showed the average AUC of MK-826 to be greater than that of CTRX (284 versus 142 μg · hr/ml) following a single 10-mg/kg dose. Also, a half-life of MK-826 longer than that of CTRX (3.2 versus 2.3 h) was observed in this species. The total amount of drug excreted in the bile in 8 h was greater for CTRX (55 to 64% of the dose) than for MK-826 (6 to 12.5% of the dose). Urinary recovery was similar for both antibiotics, with 16 to 18% of the dose recovered over an 8-h period. This excellent broad-spectrum in vivo efficacy of MK-826, together with advantageous pharmacokinetics, supports the argument for its further clinical development.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference22 articles.
1. Antimicrobial resistance issues of the future.;Craig W. A.;Diagn. Microbiol. Infect. Dis.,1996
2. Bacterial resistance to beta-lactam antibiotics.;Danziger L. H.;Am. J. Health Syst. Pharm.,1995
3. Dorso
K.
Kohler
J.
Silver
L. L.
Kropp
H.
Bactericidal effect of L-749 345 on Staphylococcus aureus and Serratia marcescens in the presence and absence of human serum abstr. F123
Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy.
1996
121
American Society for Microbiology
Washington D.C
4. Gerckens
L. S.
Pelak
B. A.
Thompson
R.
Rosen
H.
Kropp
H.
Pharmacokinetic evaluation of L-749 345 (ZD-4433) a long-acting parenteral carbapenem in rodents abstr. F127
Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy.
1996
122
American Society for Microbiology
Washington D.C
5. Gill
C. J.
Jackson
J. J.
Sundelof
J. G.
Rosen
H.
Kropp
H. In vivo activity of a novel long-acting carbapenem antibiotic L-749 345 in mouse models of localized and systemic bacterial infections abstr. F125
Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy.
1996
121
American Society for Microbiology
Washington D.C
Cited by
68 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献